Neutra Corp. (OTCPK:NTRR) executed a binding letter of intent to acquire Mercury Clinical Research, Inc. on January 30, 2023. The parties intend to enter into a binding agreement within the next 90 days.

Neutra expects to fund the acquisition with a combination of cash and equity to provide the Company with the optimum financial flexibility in the future. Mercury will become a wholly owned subsidiary of the Company and is expected to place executives in senior management positions. Transaction is subject to customary conditions, including but not limited to the following key conditions: Execution of the Definitive Agreement, Completion of mutually satisfactory due diligence and receipt of all required regulatory, corporate and third party approvals.

Transaction is expected to close in third quarter of 2023.